Forest Takes Over Namenda Lifecycle-Management Project In Deal With Adamas
This article was originally published in The Pink Sheet Daily
Executive Summary
Forest will develop and commercialize a once-daily, fixed-dose combination of its own extended-release memantine with donepezil (Pfizer’s Aricept) in the U.S. under a licensing deal with Adamas, which started the project and will retain EU rights to the memantine/donepezil combo.